|
|
Mesothelioma
Treatment
Mesothelioma
Alerts
Arthritis
Drug Shows Promising Effects for
Mesothelioma Victims
Interscience.Wiley.com,
May 19, 2004
Ancona,
Italy - Researchers in Italy have
discovered that studies involving Pfizer
Inc.'s arthritis drug Celebrex have shown
promising results in combating the effects
of cancerous cell growth related to the
asbestos-induced disease mesothelioma.
Dr. Alfonso Catalano and other researchers
at the University of Marche reported the
results of their study, Preclinical
Evaluation of the Nonsteroidal
Anti-Inflammatory agent Celecoxib on
Malignant Mesothelioma Chemo-prevention,
in the April issue of the International
Journal of Cancer. The researchers found
that the COX-2 inhibitor Celebrex, also
known as celecoxib, stopped mesothelioma
cells from growing and increased the
survival rate of mice implanted with the
cancerous disease.
"This data demonstrates that celecoxib may
have antitumor properties in malignant
mesothelioma cells from growing in a
laboratory dish and inhibited the
proliferation of malignant mesothelioma
cells in mice. In mice implanted with
mesothelioma, treatment with celecoxib
greatly extended the average survival rate
from 45 days to 62 days, and three of the
infected mice lived longer than 120 days,
the researchers reported.
"These results provide the first evidence
that celecoxib is effective for the
prevention and regression of malignant
mesothelioma cells in experimental models
. . . and strongly support ongoing
clinical trials in malignant mesothelioma
patients," the researchers said.
The full study is available on the
Internet at http://www3.interscience.wiley.com/cgi-bin/abstract/106600908/ABSTRACT
If
you have any questions regarding your
legal options or asbestos, please
contact
us.
|
|
